Elixher Uncategorized HHS OIG Issues Unfavorable Opinion on Gene Therapy Developer’s Fertility Preservation Program

HHS OIG Issues Unfavorable Opinion on Gene Therapy Developer’s Fertility Preservation Program

Bluebird Bio previously said it had sought an advisory opinion from the OIG on its fertility preservation program. The US Food and Drug Administration …

Related Post